SEC Company Response from Oric Pharmaceuticals, Inc. (ORIC) (CIK 0001796280) (ORIC) — Apr 21, 2020
Oric Pharmaceuticals, Inc. (ORIC) (CIK 0001796280)
Date: April 21, 2020 · CIK: 0001796280 · Accession: 0001193125-20-113493
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236792
Letter
April 21, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
Attention: Jeffrey Gabor Celeste Murphy Ibolya Ignat Kevin Vaughn
Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-1
File No. 333-236792
Acceleration Request
Requested Date: April 23, 2020 Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, ORIC Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-236792) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041.
[Signature page follows]
Securities and Exchange Commission
April 21, 2020
Page 2
Sincerely,
oric PHARMACEUTICALS, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 21, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Jeffrey Gabor Celeste Murphy Ibolya Ignat Kevin Vaughn Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-236792 Acceleration Request Requested Date: April 23, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ORIC Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-236792) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041. [Signature page follows] Securities and Exchange Commission April 21, 2020 Page 2 Sincerely, oric PHARMACEUTICALS, Inc. /s/ Jacob M. Chacko Jacob M. Chacko, M.D. President and Chief Executive Officer cc: Dominic Piscitelli, ORIC Pharmaceuticals, Inc. Kenneth Clark, Wilson Sonsini Goodrich & Rosati, P.C. Tony Jeffries, Wilson Sonsini Goodrich & Rosati, P.C. Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C. Melissa Rick, Wilson Sonsini Goodrich & Rosati, P.C. Charles Kim, Cooley LLP